Role of probiotics Bifidobacterium breve and Lactobacillus rhamnosus on inflammation lung in an experimental model of chronic obstructive pulmonary disease.

• Grant number: 15/18455-0
• Support Opportunities: Regular Research Grants
• Start date: April 01, 2016
• End date: March 31, 2018
• Field of knowledge: Biological Sciences - Microbiology - Applied Microbiology
• Principal Investigator: Flávio Aimbire Soares de Carvalho
• Grantee: Flávio Aimbire Soares de Carvalho
• Host Institution: Instituto de Ciência e Tecnologia (ICT). Universidade Federal de São Paulo (UNIFESP). Campus São José dos Campos. São José dos Campos , SP, Brazil
• Associated researchers: Alexandre de Castro Keller ; Elen Anatriello

Abstract

Chronic pulmonary obstructive disease (COPD) is defined as an abnormal inflammatory response of the lungs to noxious particles or gases, mainly cigarette smoke. Emphysema and chronic bronchitis are the most common diagnosis of individual patients. The cellular profile recruited to pulmonary tissue promotes inflammatory events such as irreversible pathological destruction in lung structure, loss of function and airway remodeling. COPD is a global health problem which directly affects patients lifestyle characterized by progressive physical incapability with economics and social consequences. Besides inhaled bronchodilators in combination with corticosteroids adopted as basis of symptomatic treatment of COPD and asthma patients, the long-term therapy can lead to local and systemic side effects. Without a specific treatment for COPD patients the use of probiotics via supplementation of diet can be a promising target. Since probiotics have been described as immune-modulatory agents against chronic inflammatory diseases in several studies, this project aims to investigate the beneficial effects of Bifidobacterium breve and Lactobacillus rhamnosus probiotics in lung inflammatory process in mice in a model of lung emphysema. (AU)